宜明昂科生物医药技术（上海）股份有限公司（股票名称：宜明昂科-B，股票代码：01541）于2026年9月10日发布公告，披露近期在香港联交所场内回购股份事宜。
公告显示，公司于2026年9月10日回购H股股份共58,000股，占该回购前公司已发行股本约0.0139%。每股回购价格介乎3.35港元至3.435港元，总耗资约19.61万港元。回购完成后，公司已发行股份（不含库藏股）变动为418,352,705股，库藏股数量增至2,124,600股，总股本继续维持420,477,305股。
据悉，公司于2026年5月28日通过回购授权，总数为43,150,769股。截至本次回购，公司已累计购回2,124,600股，约占授权时已发行股本的0.492%。公司在公告中确认，已遵守包括香港联合交易所有限公司证券上市规则等在内的相关法律法规规定。
本公告由执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.